BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rovin BH, Solomons N, Pendergraft WF, Dooley MA, Tumlin J, Romero-diaz J, Lysenko L, Navarra SV, Huizinga RB, Adzerikho I, Mikhailova E, Mitkovskaya N, Pimanov S, Soroka N, Bogov BI, Deliyska B, Ikonomov V, Tilkiyan E, Almeida R, Jimenez F, Teran F, Tchokhonelidze I, Tsiskarishvili N, Herrera Mendez M, Chavez Perez NN, Loaeza AR, Gutierrez Urena SR, Romero Diaz J, Araiza Casillas R, Madero Rovalo M, Niemczyk S, Sokalski A, Wiecek A, Klinger M, Bugrova OV, Chernykh TM, Kameneva TR, Lysenko LV, Raskina TA, Reshetko OV, Vezikova NN, Kropotina TV, Maksudova AN, Marasaev V, Dobronravov VA, Gordeev I, Essaian AM, Frolov A, Jelacic R, Jovanovic D, Mitic B, Pekovic G, Radovic M, Radunovic G, Carreira P, Diaz Gonzalez F, Fulladosa X, Ucar E, De Silva S, Herath C, Hewageegana A, Nazar ALM, Wazil A, Dudar I, Godlevska O, Korneyeva S, Vasylets V, Sydor N, Kolesnyk M, Parikh SV, Olsen N, Ginzler EM, Tumlin JA, Saxena A, Saxena R, Lafayette RA, Pendergraft WF, Podoll AS, Arrey-mensah AA, Bubb M, Grossman J, Oporta AI, Nami A, Rahman MM, Haq SA, Chan TMD, Temy MMY, Gomez HMP, Bermas J, Reyes BH, Hao LT, Roberto LC, Amante E, Navarra SV, Lanzon AE, Choe J, Kang TY, Kim YS, Lee S, Lee JS, Jun JCC, Vasudevan A, Luo S, Cheng T, Satirapoj B, Noppakun K. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney International 2019;95:219-31. [DOI: 10.1016/j.kint.2018.08.025] [Cited by in Crossref: 90] [Cited by in F6Publishing: 63] [Article Influence: 30.0] [Reference Citation Analysis]
Number Citing Articles
1 Wenderfer SE, Chang J, Hicks MJ. Approach to Classification and Management of Childhood-Onset Lupus Nephritis. Curr Pediatr Rep 2020;8:26-35. [DOI: 10.1007/s40124-020-00207-8] [Reference Citation Analysis]
2 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
3 Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res 2020;9:F1000 Faculty Rev-905. [PMID: 32789005 DOI: 10.12688/f1000research.22438.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside. Int J Mol Sci 2021;22:3766. [PMID: 33916456 DOI: 10.3390/ijms22073766] [Reference Citation Analysis]
5 Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? Adv Chronic Kidney Dis 2020;27:56-66. [PMID: 32147003 DOI: 10.1053/j.ackd.2019.08.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
6 Gao Y, Wang Y, Li R, Zhou X. Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov. Front Med (Lausanne) 2021;8:680302. [PMID: 34222288 DOI: 10.3389/fmed.2021.680302] [Reference Citation Analysis]
7 Chaichian Y, Wallace DJ. Innovative Trials and New Opportunities in SLE. Rheum Dis Clin North Am 2021;47:481-99. [PMID: 34215375 DOI: 10.1016/j.rdc.2021.04.010] [Reference Citation Analysis]
8 Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers 2020;6:7. [PMID: 31974366 DOI: 10.1038/s41572-019-0141-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
9 Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344-58. [PMID: 31180031 DOI: 10.1016/S0140-6736(19)30546-X] [Cited by in Crossref: 115] [Cited by in F6Publishing: 62] [Article Influence: 38.3] [Reference Citation Analysis]
10 Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev 2021;3:CD007478. [PMID: 33687069 DOI: 10.1002/14651858.CD007478.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 van Gelder T. How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney Int 2021:S0085-2538(21)00686-4. [PMID: 34284043 DOI: 10.1016/j.kint.2021.06.036] [Reference Citation Analysis]
12 Ponticelli C, Reggiani F, Moroni G. Old and New Calcineurin Inhibitors in Lupus Nephritis. J Clin Med 2021;10:4832. [PMID: 34768354 DOI: 10.3390/jcm10214832] [Reference Citation Analysis]
13 Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev 2019;18:510-8. [PMID: 30844548 DOI: 10.1016/j.autrev.2019.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
14 Thurman JM. BLISS in the Treatment of Lupus Nephritis. Clin J Am Soc Nephrol 2021;16:969-71. [PMID: 33536242 DOI: 10.2215/CJN.17991120] [Reference Citation Analysis]
15 Tamirou F, Houssiau FA. Management of Lupus Nephritis. J Clin Med 2021;10:670. [PMID: 33572385 DOI: 10.3390/jcm10040670] [Reference Citation Analysis]
16 Liossis SN, Staveri C. What's New in the Treatment of Systemic Lupus Erythematosus. Front Med (Lausanne) 2021;8:655100. [PMID: 33748165 DOI: 10.3389/fmed.2021.655100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020;7:433-46. [PMID: 32488652 DOI: 10.1007/s40744-020-00212-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
18 Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022:annrheumdis-2021-221478. [PMID: 35144924 DOI: 10.1136/annrheumdis-2021-221478] [Reference Citation Analysis]
19 Yap DY, Li PH, Tang C, So BY, Kwan LP, Chan GC, Lau CS, Chan TM. Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis. Kidney International Reports 2021. [DOI: 10.1016/j.ekir.2021.12.005] [Reference Citation Analysis]
20 Mejía-Vilet JM, Ayoub I. The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. Front Med (Lausanne) 2021;8:622225. [PMID: 33665199 DOI: 10.3389/fmed.2021.622225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mucke J, Schneider M. Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodes. Internist. [DOI: 10.1007/s00108-021-01250-3] [Reference Citation Analysis]
22 van Gelder T, Huizinga RB, Lisk L, Solomons N. Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrology Dialysis Transplantation 2021. [DOI: 10.1093/ndt/gfab022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
23 Maria NI, Davidson A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol 2020;16:255-67. [PMID: 32203285 DOI: 10.1038/s41584-020-0401-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
24 Sánchez ARP, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 2022. [PMID: 35039665 DOI: 10.1038/s41584-021-00739-3] [Reference Citation Analysis]
25 Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 2020;79:1070-6. [PMID: 32448782 DOI: 10.1136/annrheumdis-2020-217178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis 2021. [PMID: 34894070 DOI: 10.1111/1756-185X.14265] [Reference Citation Analysis]
27 Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol 2019;31:682-8. [PMID: 31389814 DOI: 10.1097/BOR.0000000000000642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Ponticelli C, Doria A, Moroni G. Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases). J Nephrol 2021;34:1069-80. [PMID: 32529559 DOI: 10.1007/s40620-020-00772-7] [Reference Citation Analysis]
29 Adamichou C, Flouri I, Fanouriakis A, Nikoloudaki M, Nikolopoulos D, Repa A, Boki K, Chatzidionysiou K, Garyfallos A, Boumpas D, Sidiropoulos P, Bertsias G. Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. Mediterr J Rheumatol 2020;31:87-91. [PMID: 32411939 DOI: 10.31138/mjr.31.1.87] [Reference Citation Analysis]
30 Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070-80. [PMID: 33971155 DOI: 10.1016/S0140-6736(21)00578-X] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 17.0] [Reference Citation Analysis]
31 Peleg Y, Bomback AS, Radhakrishnan J. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clin J Am Soc Nephrol 2020;15:1066-72. [PMID: 32152065 DOI: 10.2215/CJN.13761119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Liu B, Ou Q, Tang Y, Fu S, Liang P, Yu Y, Xu Z, Chen Y, Xu A. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis. Clin Rheumatol 2019;38:2519-28. [PMID: 31081535 DOI: 10.1007/s10067-019-04596-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
33 Kostopoulou M, Adamichou C, Bertsias G. An Update on the Diagnosis and Management of Lupus Nephritis. Curr Rheumatol Rep 2020;22:30. [PMID: 32500443 DOI: 10.1007/s11926-020-00906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Alamilla-Sanchez ME, Alcala-Salgado MA, Alonso-Bello CD, Fonseca-Gonzalez GT. Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis. Int J Nephrol Renovasc Dis 2021;14:441-58. [PMID: 34924767 DOI: 10.2147/IJNRD.S335371] [Reference Citation Analysis]
35 Lee IJ, Parikh SV. Lupus Nephritis: How Far Have We Come, and Where Are We Headed? Adv Chronic Kidney Dis 2019;26:311-2. [PMID: 31733714 DOI: 10.1053/j.ackd.2019.09.003] [Reference Citation Analysis]
36 Trachtman H, Caplan AL. Data monitoring committees and randomized clinical trials. Kidney Int 2019;95:992. [PMID: 30904070 DOI: 10.1016/j.kint.2018.12.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Avasare RS, Yee J. Lupus Nephritis: Breaking the Lull. Adv Chronic Kidney Dis 2019;26:307-10. [PMID: 31733713 DOI: 10.1053/j.ackd.2019.05.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Rosenkranz AR, Tesar V. Lupus nephritis and ANCA-associated vasculitis: towards precision medicine? Nephrol Dial Transplant 2021;36:37-43. [PMID: 34153980 DOI: 10.1093/ndt/gfab166] [Reference Citation Analysis]
39 Kostopoulou M, Pitsigavdaki S, Bertsias G. Lupus Nephritis: Improving Treatment Options. Drugs 2022. [PMID: 35486369 DOI: 10.1007/s40265-022-01715-1] [Reference Citation Analysis]
40 Lledó GM, Xipell M, García-herrera A, Bueno L, Cervera R, Galindo M, Gómez-puerta JA, Morales E, Praga M, Rojas JE, Ruiz-irastorza G, Pernaute OS, Jayne D, Espinosa G, Quintana LF. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.03.016] [Reference Citation Analysis]
41 Kostopoulou M, Fanouriakis A, Bertsias G, Boumpas DT. Treatment of lupus: more options after a long wait. Ann Rheum Dis 2022:annrheumdis-2021-221817. [PMID: 35027404 DOI: 10.1136/annrheumdis-2021-221817] [Reference Citation Analysis]
42 Oliva-Damaso N, Bomback AS. Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics. Am J Kidney Dis 2021;77:984-7. [PMID: 33221369 DOI: 10.1053/j.ajkd.2020.11.003] [Reference Citation Analysis]
43 Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713-23. [PMID: 32220834 DOI: 10.1136/annrheumdis-2020-216924] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 39.0] [Reference Citation Analysis]
44 Auguste B, Teakell J, Ullur AR, Topf JM, Hiremath S. Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA. Kidney Med 2021;3:889-92. [PMID: 34938997 DOI: 10.1016/j.xkme.2021.10.001] [Reference Citation Analysis]
45 Ball J, Elzebroek N, Pozniak E. Lupus Academy: Keeping Education Live, Virtually. J Eur CME 2021;10:2014041. [PMID: 34925961 DOI: 10.1080/21614083.2021.2014041] [Reference Citation Analysis]
46 Hobeika L, Ng L, Lee IJ. Moving Forward With Biologics in Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:338-50. [PMID: 31733718 DOI: 10.1053/j.ackd.2019.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Dall’era M, Solomons N, Federico R, Truman M. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus 2019;28:591-6. [DOI: 10.1177/0961203319842924] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
48 Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021;80:14-25. [PMID: 33051219 DOI: 10.1136/annrheumdis-2020-218272] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
49 Craig JC. Interpreting trial results-time for confidence and magnitude and not P values please. Kidney Int 2019;95:28-30. [PMID: 30606426 DOI: 10.1016/j.kint.2018.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol 2020;32:609-16. [PMID: 33002950 DOI: 10.1097/BOR.0000000000000754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
51 Lei Y, Loutan J, Anders HJ. B-cell depletion or belimumab or voclosporin for lupus nephritis? Curr Opin Nephrol Hypertens 2021;30:237-44. [PMID: 33186226 DOI: 10.1097/MNH.0000000000000662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
52 Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs 2021;23:331-47. [PMID: 34244988 DOI: 10.1007/s40272-021-00457-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Petri M, Barr E, Magder LS. Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis. J Rheumatol 2021;48:222-7. [PMID: 32295853 DOI: 10.3899/jrheum.191094] [Reference Citation Analysis]
54 Montigny PM, Houssiau FA. New Treatment Options in Lupus Nephritis. Arch Immunol Ther Exp (Warsz) 2022;70:11. [PMID: 35298708 DOI: 10.1007/s00005-022-00647-8] [Reference Citation Analysis]
55 Mejía-Vilet JM, Romero-Díaz J. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34392746 DOI: 10.1080/1744666X.2021.1967747] [Reference Citation Analysis]
56 Luo S, Long H, Lu Q. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Int Immunopharmacol 2020;89:107028. [PMID: 33039962 DOI: 10.1016/j.intimp.2020.107028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
57 Rubio J, Kyttaris V. Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial. ACR Open Rheumatol 2021. [PMID: 34463434 DOI: 10.1002/acr2.11338] [Reference Citation Analysis]
58 Ruiz-Irastorza G, Dueña-Bartolome L, Dunder S, Varona J, Gomez-Carballo C, Dominguez-Cainzos J, Rodrigo-Manjon A, Bueno L, Richez C, Duffau P, Blanco P, Lazaro E. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmun Rev 2021;20:102898. [PMID: 34274543 DOI: 10.1016/j.autrev.2021.102898] [Reference Citation Analysis]
59 Boesen EI, Kakalij RM. Autoimmune-mediated renal disease and hypertension. Clin Sci (Lond) 2021;135:2165-96. [PMID: 34533582 DOI: 10.1042/CS20200955] [Reference Citation Analysis]
60 Parodis I, Tamirou F, Houssiau FA. Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy? Arch Immunol Ther Exp (Warsz) 2022;70:8. [PMID: 35147824 DOI: 10.1007/s00005-022-00646-9] [Reference Citation Analysis]
61 Mok CC, Hamijoyo L, Kasitanon N, Chen DY, Chen S, Yamaoka K, Oku K, Li MT, Zamora L, Bae S, Navarra S, Morand EF, Tanaka Y. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. The Lancet Rheumatology 2021;3:e517-31. [DOI: 10.1016/s2665-9913(21)00009-6] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
62 Kim ES, Keam SJ. Voclosporin in lupus nephritis: a profile of its use. Drugs Ther Perspect. [DOI: 10.1007/s40267-021-00887-2] [Reference Citation Analysis]
63 Ruiz-irastorza G, Ugarte A, Ruiz-arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus 2020;29:1155-67. [DOI: 10.1177/0961203320930099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
64 Narváez J. Lupus eritematoso sistémico 2020. Medicina Clínica 2020;155:494-501. [DOI: 10.1016/j.medcli.2020.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol 2021;33:197-204. [PMID: 33394604 DOI: 10.1097/BOR.0000000000000777] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Schreiber J, Eisenberger U, de Groot K. [Lupus nephritis]. Internist (Berl) 2019;60:468-77. [PMID: 30840107 DOI: 10.1007/s00108-019-0574-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
67 Kant S, Kronbichler A, Sharma P, Geetha D. Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. Am J Kidney Dis 2021:S0272-6386(21)00835-0. [PMID: 34508831 DOI: 10.1053/j.ajkd.2021.07.019] [Reference Citation Analysis]
68 Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int 2021:S0085-2538(21)00874-7. [PMID: 34619230 DOI: 10.1016/j.kint.2021.09.012] [Reference Citation Analysis]
69 Cervera R, Mosca M, Ríos-garcés R, Espinosa G, Trujillo H, Bada T, Praga M. Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. Autoimmunity Reviews 2019;18:102406. [DOI: 10.1016/j.autrev.2019.102406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Rafael-Vidal C, Altabás I, Pérez N, Mourino Rodríguez C, Pego-Reigosa JM, Garcia S. Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis. Int J Mol Sci 2021;22:1263. [PMID: 33514066 DOI: 10.3390/ijms22031263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Klumb EM, Scheinberg M, Souza VA, Xavier RM, Azevedo VF, McElwee E, Restrepo MR, Monticielo OA. The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. Lupus 2021;:9612033211030008. [PMID: 34255586 DOI: 10.1177/09612033211030008] [Reference Citation Analysis]
72 Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci 2019;20:E6231. [PMID: 31835612 DOI: 10.3390/ijms20246231] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
73 Parodis I, Houssiau FA. From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann Rheum Dis 2021:annrheumdis-2021-221270. [PMID: 34521616 DOI: 10.1136/annrheumdis-2021-221270] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med 2021;10:E243. [PMID: 33440874 DOI: 10.3390/jcm10020243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
75 Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69-81. [PMID: 33280011 DOI: 10.1093/rheumatology/keaa403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
76 An Y, Zhang H, Liu Z. Individualizing Therapy in Lupus Nephritis. Kidney Int Rep 2019;4:1366-72. [PMID: 31701046 DOI: 10.1016/j.ekir.2019.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Obrișcă B, Vornicu A, Jurubiță R, Achim C, Bobeică R, Andronesi A, Sorohan B, Herlea V, Procop A, Dina C, Ismail G. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol 2021;40:3285-97. [PMID: 33595739 DOI: 10.1007/s10067-021-05646-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol 2020;32:208-14. [PMID: 32141953 DOI: 10.1097/BOR.0000000000000704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
79 Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets 2020;24:1283-302. [PMID: 33034541 DOI: 10.1080/14728222.2020.1832464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
80 Cheriyan AM, Ume AC, Francis CE, King KN, Linck VA, Bai Y, Cai H, Hoover RS, Ma HP, Gooch JL, Williams CR. Calcineurin A-α suppression drives nuclear factor-κB-mediated NADPH oxidase-2 upregulation. Am J Physiol Renal Physiol 2021;320:F789-98. [PMID: 33615888 DOI: 10.1152/ajprenal.00254.2020] [Reference Citation Analysis]
81 Almaani S, Parikh SV. Membranous Lupus Nephritis: A Clinical Review. Adv Chronic Kidney Dis 2019;26:393-403. [PMID: 31733724 DOI: 10.1053/j.ackd.2019.08.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
82 Ume AC, Wenegieme TY, Williams CR. Calcineurin inhibitors: a double-edged sword. Am J Physiol Renal Physiol 2021;320:F336-41. [PMID: 33225712 DOI: 10.1152/ajprenal.00262.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Paredes JL, Fernandez-Ruiz R, Niewold TB. T Cells in Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2021;47:379-93. [PMID: 34215369 DOI: 10.1016/j.rdc.2021.04.005] [Reference Citation Analysis]
84 Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, Boumpas DT. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open 2020;6:e001263. [PMID: 32699043 DOI: 10.1136/rmdopen-2020-001263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
85 Mok CC. A new old treatment for lupus nephritis. Lancet 2021;397:2027-9. [PMID: 33971151 DOI: 10.1016/S0140-6736(21)00663-2] [Reference Citation Analysis]
86 Cortazar FB, Niles JL. The Fate of Plasma Exchange and Glucocorticoid Dosing in ANCA-Associated Vasculitis After PEXIVAS. American Journal of Kidney Diseases 2020;76:595-7. [DOI: 10.1053/j.ajkd.2020.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
87 Ume AC, Pugh JM, Kemp MG, Williams CR. Calcineurin inhibitor (CNI)‐associated skin cancers: New insights on exploring mechanisms by which CNIs downregulate DNA repair machinery. Photodermatol Photoimmunol Photomed 2020;36:433-40. [DOI: 10.1111/phpp.12600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
88 Kolic J, Beet L, Overby P, Cen HH, Panzhinskiy E, Ure DR, Cross JL, Huizinga RB, Johnson JD. Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets. Endocrinology 2020;161:bqaa162. [PMID: 32894758 DOI: 10.1210/endocr/bqaa162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]